Skip to content

Opening book details…

Can I read MicroRNA‐155‐5p in serum derived‐exosomes promotes ischaemia–reperfusion injury by reducing CypD ubiquitination by NEDD4 on EtoBox?

MicroRNA‐155‐5p in serum derived‐exosomes promotes ischaemia–reperfusion injury by reducing CypD ubiquitination by NEDD4 by Chenkai Hu; Junyu Liao; Ruiyan Huang; Qiang Su; Lei He is a Medicine article available to read on EtoBox.

What is MicroRNA‐155‐5p in serum derived‐exosomes promotes ischaemia–reperfusion injury by reducing CypD ubiquitination by NEDD4 about?

## Abstract ## Aims Recovery of blood flow is a therapeutic approach for myocardial infarction but paradoxically induces injury to the myocardium. Exosomes (exos) are pivotal mediators for intercellular communication that can be released by different cells and are involved in cardiovascular diseases. This study aimed to explore the possible effects and mechanisms of miR‐155‐5p loaded by serum‐derived exos in myocardial infarction reperfusion injury (MIRI). ## Methods and results Exos were isolated from mouse serum after induction of ischaemia reperfusion (I/R) and injected into I/R‐treated mice to assess cardiac function, infarction size, and cardiomyocyte apoptosis. Primary cardiomyocytes were transfected with miR‐155‐5p inhibitor before treatment with oxygen–glucose deprivation and re‐oxygenation (OGD/R) and exos derived from the serum of I/R‐treated mice (I/R‐Exos), in which Bcl‐2, Bax, and cleaved‐caspase‐3 levels were detected. The interactions among miR‐155‐5p, NEDD4, and CypD were evaluated. miR‐155‐5p level was evidently increased in I/R‐Exos than in exos from the serum of sham‐operated mice (__P__ < 0.05). In comparison with the I/R group, the I/R‐Exos + I/R group had incr

Who reads MicroRNA‐155‐5p in serum derived‐exosomes promotes ischaemia–reperfusion injury by reducing CypD ubiquitination by NEDD4?

It is typically read by researchers, students, and practitioners in Medicine.

Author
Chenkai Hu; Junyu Liao; Ruiyan Huang; Qiang Su; Lei He
Publisher
John Wiley and Sons Inc.
Published
2023
Language
EN
Field
Medicine (Health Sciences)